ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In preclinical studies, imatinib showed specific antileukemic activity in vitro and in vivo against BCR-ABL-positive cells, including the eradication of leukemia induced by the injection of cell lines derived from patients with blast-crisis CML (5–7).